The upcoming Phase 2 data readout is a high-impact binary event. Traders should monitor the May 27 results and conference call for efficacy and safety signals. Positive data could drive substantial upside given the large I&I market opportunity; negative data could lead to significant downside.
APGE drugs
APGE drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 27 $77.75entry
- T+1 · 6mo ago +0.09%α −0.46% · $77.82
- T+5 · 6mo ago +1.23%α +0.03% · $78.71
- T+20 · 5mo ago +70.65%α +72.55% · $132.68
- T+60 · 3mo ago +73.31%α +71.43% · $134.75
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Apogee Therapeutics announced it will release Part B 16-week data from the Phase 2 APEX trial of zumilokibart on May 27, 2026, followed by a conference call. This is a binary catalyst event for the clinical-stage biotech, as zumilokibart is its most advanced program targeting atopic dermatitis, asthma, and eosinophilic esophagitis.
Key Facts
- Part B 16-week data from Phase 2 APEX trial of zumilokibart to be reported on May 27, 2026.
- Conference call and webcast scheduled for 8:00 a.m. ET on May 27, 2026.
- Zumilokibart is Apogee's most advanced program, targeting atopic dermatitis, asthma, and EoE.
- Apogee is a clinical-stage biotechnology company with no approved products or reported revenue.
Financial Impact
No financial data provided; outcome of data readout could significantly impact valuation given early-stage nature.
Risk Factors
- Negative or mixed Phase 2 data could severely impact stock price, as zumilokibart is the lead asset.
- Clinical-stage biotech with no revenue; cash runway and future financing needs depend on trial outcomes.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3301436 |
Track record
31 reports on APGE
9 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +73.31% at T+60 after the May 27, 2026 report. 12 of 13 went positive at some point.
Filters
- Sep 14, 20269w ago 15-12G Neutral 4/10 No price data
- Sep 3, 202610w ago 25-NSE Bullish 8/10 Entry $135.06 No price data
- Sep 3, 202610w ago 8-K Bullish 8/10 Entry $135.06 No price data
- Aug 11, 202613w ago 8-K Bullish 7/10 Entry $134.55 No price data
- Aug 10, 202614w ago 8-K Bullish 8/10 No price data
- Aug 10, 202614w ago Press Release Bullish 8/10 Entry $134.65 No price data
- Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $134.49 to $135.07 ▲ +0.43% −0.17% vs SPY
- Aug 3, 202615w ago DEFA14A Bullish 5/10 Entry $134.19 to $135.08 ▲ +0.66% +1.90% vs SPY
- Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $133.82 to $134.65 ▲ +0.62% −2.56% vs SPY
- Jun 26, 202620w ago DEFA14A Bullish 6/10 Entry $132.61 to $134.28 ▲ +1.26% +1.54% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers